Please provide your email address to receive an email when new articles are posted on . Patients with stage III deficient mismatch repair colon cancer derived significant benefit from the addition of ...
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing The following ...
The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.
One in every three people is expected to have cancer in their lifetime, making it a major health concern for mankind. A crucial indicator of the outcome of cancer is its tumor microsatellite ...
The Dako Omnis test identifies mismatch repair deficiencies in colorectal cancer, aiding in treatment decisions and potentially improving patient outcomes. Hernexeos, a kinase inhibitor, offers a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback